# A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder

> **NCT02389816** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 493 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** Vortioxetine

## Key facts

- **NCT ID:** NCT02389816
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-10
- **Primary completion:** 2018-03-16
- **Final completion:** 2018-03-16
- **Target enrollment:** 493 (ACTUAL)
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02389816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02389816, "A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02389816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*